{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 4.0404005, "regularMarketPrice": 3.09, "marketState": "PRE", "currency": "USD", "exchange": "NMS", "shortName": "Relmada Therapeutics, Inc.", "longName": "Relmada Therapeutics, Inc.", "messageBoardId": "finmb_9070579", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "fiftyDayAverageChangePercent": 0.1419068, "twoHundredDayAverage": 11.03715, "twoHundredDayAverageChange": -7.94715, "twoHundredDayAverageChangePercent": -0.72003645, "marketCap": 102401056, "forwardPE": -1.2459677, "priceToBook": 0.66223747, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.5 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1403271000000, "priceHint": 4, "regularMarketChange": 0.119999886, "regularMarketTime": 1684180805, "regularMarketDayHigh": 3.13, "regularMarketDayRange": "2.94 - 3.13", "regularMarketDayLow": 2.94, "regularMarketVolume": 133235, "regularMarketPreviousClose": 2.97, "bid": 0.0, "ask": 0.0, "bidSize": 8, "askSize": 8, "fullExchangeName": "NasdaqGS", "financialCurrency": "USD", "regularMarketOpen": 2.97, "averageDailyVolume3Month": 200378, "averageDailyVolume10Day": 172330, "fiftyTwoWeekLowChange": 1.28, "fiftyTwoWeekLowChangePercent": 0.70718235, "fiftyTwoWeekRange": "1.81 - 38.68", "fiftyTwoWeekHighChange": -35.59, "fiftyTwoWeekHighChangePercent": -0.92011374, "fiftyTwoWeekLow": 1.81, "fiftyTwoWeekHigh": 38.68, "dividendDate": 1569801600, "earningsTimestamp": 1683837000, "earningsTimestampStart": 1691611200, "earningsTimestampEnd": 1692043200, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -4.81, "epsForward": -2.48, "epsCurrentYear": -3.61, "priceEpsCurrentYear": -0.85595566, "sharesOutstanding": 30099200, "bookValue": 4.666, "fiftyDayAverage": 2.706, "fiftyDayAverageChange": 0.38399982, "displayName": "Relmada Therapeutics", "symbol": "RLMD"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "2222 Ponce de Leon Boulevard", "address2": "Floor 3", "city": "Coral Gables", "state": "FL", "zip": "33134", "country": "United States", "phone": "786 629 1376", "website": "https://www.relmada.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.", "fullTimeEmployees": 14, "companyOfficers": [{"maxAge": 1, "name": "Dr. Sergio  Traversa M.B.A., MBA, Pharm.D., PharmD", "age": 62, "title": "CEO & Director", "yearBorn": 1960, "fiscalYear": 2022, "totalPay": {"raw": 719041, "fmt": "719.04k", "longFmt": "719,041"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 34490, "fmt": "34.49k", "longFmt": "34,490"}}, {"maxAge": 1, "name": "Mr. Maged S. Shenouda M.B.A., MBA, R.Ph, R.Ph.", "age": 58, "title": "Chief Financial Officer", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": {"raw": 450353, "fmt": "450.35k", "longFmt": "450,353"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 25070, "fmt": "25.07k", "longFmt": "25,070"}}, {"maxAge": 1, "name": "Mr. Charles S. Ence CPA, M.B.A.", "age": 57, "title": "Chief Accounting & Compliance Officer", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": {"raw": 568679, "fmt": "568.68k", "longFmt": "568,679"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 2203, "fmt": "2.2k", "longFmt": "2,203"}}, {"maxAge": 1, "name": "Dr. Paolo  Manfredi M.D., Ph.D.", "age": 60, "title": "Chief Scientific Officer", "yearBorn": 1962, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Gina  DiGuglielmo", "title": "VP & Head of Clinical Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Marco  Pappagallo M.D.", "age": 63, "title": "Chief Clinical Officer", "yearBorn": 1959, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. John  Hixon", "title": "Head of Commercial", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Cedric  O'Gorman M.B.A., M.D., MBA", "age": 46, "title": "Chief Medical Officer", "yearBorn": 1976, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Richard M. Mangano", "age": 72, "title": "Consultant", "yearBorn": 1950, "fiscalYear": 2018, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 4, "boardRisk": 10, "compensationRisk": 9, "shareHolderRightsRisk": 4, "overallRisk": 8, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}